<DOC>
	<DOC>NCT02332031</DOC>
	<brief_summary>To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and elimination of sorafenib and safety in healthy male subjects</brief_summary>
	<brief_title>Sorafenib Drug Drug Interaction Study in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Healthy male subjects between the ages of 18 (inclusive) and 45 years (inclusive) at the first screening visit. Body mass index (BMI) between 18.5 (inclusive) to 30.0 kg / m² (inclusive) with body weight ≥ 65kg. Normal thyroid function indicated by thyroid examination to include total and free T3 (Triiodothyronine) , T4 (total and free Thyroxine, levothyroxine), TSH (Thyroid stimulating hormone), antiTSHreceptor (antiTSHR) antibody, antithyroperoxidase (antiTPO) antibody, antithyroglobulin antibody (antiATA) as well as thyroid ultrasound. History of clinically significant metabolic, renal, hepatic, or central nervous system disorder such as seizure, psychosis and sleep disorders. History of cardiovascular diseases including arrhythmia, hypertension, ischemia, etc. Known or suspected cardiovascular disease including potential risk of atrioventricular (AV) block, arrhythmia, etc. with or without a formal cardiologist consultation. Subjects who had received iodine containing contrast medium within 2 months before first study drug administration. Use of systemic or topical medicines or substances which might affect the study drug(s) must be avoided</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sorafenib, levothyroxine, drug interaction, pharmacokinetics, healthy volunteer</keyword>
</DOC>